Refractory period (sex) for treating sexual dysfunction. Sildenafil, used in the treatment of erectile dysfunction, was found in one scientific study to have caused "a decreased postejaculatory erectile refractory time (3.2 ± 0.7 vs. 6.4 ± 0.7 minutes)" in men diagnosed with premature ejaculation. It is additionally proposed that the gonadotropin inhibitory hormone (GnIH), which is considered to inhibit the hypothalamic-pituitary-gonadal axis and sexual functions causes refractoriness of the post-ejaculatory refractory period. This hypothesis also supports the increase of oxytocin and prolactin after orgasm in accordance with the previous studies. One alternative theory explains the male refractory period in terms of a peripheral
Cabazitaxel mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Cabazitaxel Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival